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Background: Adjuvant chemotherapy reduces recurrences of non–
small-cell lung cancer (NSCLC). To determine which patients need 
adjuvant chemotherapy, we assessed factors associated with time to 
relapse (TTR).
Methods: In 230 resected stage I–II NSCLCs, we correlated immu-
nohistochemistry scores for factors associated with cell growth rate, 
growth regulation, hypoxia, cell survival, and cell death with TTR.
Results: With a median follow-up of 82 months (1–158) for those 
alive and relapse free at last follow-up, median time to recurrence 
was not reached. The 2- and 5-year probabilities of maintaining 
freedom from recurrence were 80.7% (95% confidence interval, 
75.3%, 86.4%) and 74.6% (95% confidence interval, 68.6%, 
81.2%), respectively. TTR curves flattened at an apparent cure rate 
of 70%. In multicovariate Cox models, factors correlating with 
shorter TTR were membranous carbonic anhydrase IX (mCAIX) 
staining (any versus none, hazard ratio = 2.083, p = 0.023) and 
node stage (N1 versus N0, hazard ratio = 2.591, p = 0.002). mCAIX 
scores correlated positively with tumor size, grade, squamous his-
tology, necrosis, mitoses, Ki67, p53, nuclear DNA methyltrans-
ferase 1, and cytoplasmic  enhancer-of-split-and-hairy-related 
protein, and they correlated inversely with papillary histology, 
epidermal growth factor receptor mutation (trend), copper trans-
porter-1, and cytoplasmic  hypoxia-inducible factor-1α, vascular 
endothelial growth factor, DNA methyltransferase 1, and excision 
repair cross-complementing rodent repair deficiency, complemen-
tation group 1.
Conclusion: Nodal stage and mCAIX immunohistochemistry were 
the strongest independent predictors of shorter TTR in resected 
NSCLCs. mCAIX correlated with tumor size, markers of tumor 
proliferation and necrosis, and tumor genetic characteristics, and 
it paradoxically correlated inversely with the hypoxia markers, 
hypoxia-inducible factor-1α and vascular endothelial growth factor. 
Presence of mCAIX could help determine patients with high risk of 
recurrence who might require adjuvant chemotherapy.
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Lung cancer is the world’s leading cause of cancer death,1 and U.S. lung cancer 5-year relative survival rate has only 
increased from 12% in 1975–1977 to 16% currently.2 The 
poor prognosis of lung cancer is due in part to a high propor-
tion of patients presenting initially with advanced disease, but 
even patients with operable early-stage disease are at mod-
erately high risk of relapse.3 Adjuvant chemotherapy reduces 
the probability of relapse after lung cancer resection, but we 
are currently not able to accurately determine which patients 
actually need adjuvant therapy. In patients with resected stage 
I and II non–small-cell lung cancer (NSCLC), we assessed 
association with time to relapse (TTR) and overall survival 
(OS) of various tumor markers related to tumor growth rate, 
growth control, tumor cell survival and death, and hypoxia. 
In defining clinically important biomarkers to predict tumor 
biological behavior, OS is a more precise end point than 
TTR, but it has the major disadvantage that it is affected by 
several factors unrelated to tumor biology, including patient 
age, comorbidities, and therapy details.4 Hence, our primary 
objective was to define factors associated with TTR (defined 
as the time from surgery to tumor recurrence, with patients 
censored at time of last follow-up (LFU), death from other 
causes, or development of a new primary malignancy [in lung 
or any other site] that was associated with metastases, if they 
remained free of evidence of recurrence of their initial pri-
mary lung cancer at that time).
MATERIALS AND METHODS
Using an Institutional Review Board–approved labo-
ratory protocol, we accessed the University of Texas/M. D. 
Anderson Cancer Center Lung SPORE Tissue Bank and 
selected resected archival formalin-fixed, paraffin-embedded 
tumor samples from 230 stage I–II NSCLC patients with 
squamous cell (n = 87) or adenocarcinomas (n = 143) who 
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had given informed consent at the time of tissue collection 
and who had not received any adjuvant or neoadjuvant chemo-
therapy or radiotherapy.
Tissue microarrays (TMAs) were prepared using stan-
dard methods5: a biopsy needle was inserted into each forma-
lin-fixed, paraffin-embedded tumor specimen three times to 
obtain three tissue cores, each measuring 1 mm in diameter 
by 2 to 3 mm long. Based on prior assessment of hematoxylin 
and eosin slides, the TMA cores were obtained preferentially 
from areas with high tumor cell content and with minimal 
necrosis or fibrosis, with one sample taken from around the 
center of the tumor, one from the periphery, and one from an 
intermediate area. Serial sections were cut from the TMA con-
structed from these cores and mounted on glass slides. Slides 
were deparaffinized in Xylene for 10 minutes three times. 
The tissue sections were hydrated in graded ethanols 100%, 
90%, 70%, and 50% for 5 minutes each time. Heat-induced 
epitope retrieval was performed in a Dako (Carpinteria, CA) 
antigen retrieval bath at 121°C for 30 minutes and 90°C for 
10 minutes using a Decloaking chamber (Biocare, Concord, 
CA), followed by a 30 minutes cool down. Before antibody 
immunostaining, endogenous peroxidase activity was blocked 
with 3% H
2
O
2
 in methanol for 30 minutes. To block nonspe-
cific antibody binding, tissue sections were incubated with 
10% fetal bovine serum in Tris Buffered Saline in Tween 
20 for 30 minutes. Incubation with primary antibodies is as 
presented in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A547). This was fol-
lowed by incubation with Envision plus labeled polymer, 
 anti-rabbit-horseradish-peroxidase antibody (Dako) for 30 
minutes at room temperature. Staining development was per-
formed with diaminobenzidine, with timed monitoring using 
a positive control sample. The slides were then counterstained 
with hematoxylin, dehydrated, cleared, and mounted.
Experienced lung pathologists (MIN and IIW, blinded 
for patient outcome) then manually recorded percent of tumor 
cells staining with 0 (absent), 1+ (mild), 2+ (moderate), and 
3+ (strong) intensity. As appropriate, factor staining intensity 
was assessed for one or more of tumor cell nucleus, cytoplasm, 
and membrane. Immunohistochemistry (IHC) scores (0–300) 
were then calculated for each relevant cell region by multi-
plying stain intensity (0–3) by percent tumor cells staining 
with each intensity. For each tumor specimen, results from the 
three cores were then averaged. If for a given patient results 
for only a single core were evaluable by IHC, then that single 
value was used, while the results for two cores were averaged 
if only two of the three cores were evaluable.
Molecular factors that we assessed included nuclear 
factors (p53, p21WAF1/CIP1, and Ki67), cytoplasmic fac-
tors  (cyclooxygenase-2 and decoy receptor-2), nuclear 
and cytoplasmic factors (copper transporter-1 [CTR1], 
DNA methyltransferase 1 [DNMT1], hypoxia-inducible 
factor-1α [HIF-1α], retinoblastoma [Rb], phospho-Rb, 
 enhancer-of-split-and-hairy-related protein [SHARP2, also 
known as “differentially expressed in chondrocytes  protein-1”/
DEC1], survivin, vascular endothelial growth factor [VEgF], 
p14ARF, p16INK4, and excision repair  cross-complementing 
rodent repair deficiency, complementation group 1 [ERCC1]), 
and cytoplasmic and membrane carbonic anhydrase IX 
(mCAIX) and transforming growth factor-β. We also defined 
number of apoptotic cells (by terminal deoxynucleotidyl 
transferase–mediated deoxyuridine triphosphate-biotin nick 
end-labeling assay) per 10 high-powered fields, and for a sub-
set of patients, we had information on mutation status for epi-
dermal growth factor receptor (EGFR) and KRAS genes.
Tumor specimens were assessed by pathologists IIW 
and MIN for tumor histopathologic type, percent of adeno-
carcinomas made up of acinar, lepidic, mucinous, papillary, 
solid and micropapillary regions, number of mitoses per 10 
 high-powered fields, presence of necrosis, and invasion of 
pleura or lymphovascular structures. Number of nodes exam-
ined, number of positive nodes, tumor diameter, and patho-
logic stage were also recorded.
Statistical Methods
Patient gender, age, race, and smoking history informa-
tion was recorded and summarized by descriptive statistics. 
Continuous biomarkers were summarized by mean, SD, median, 
and range. The difference of biomarkers between/among patient 
characteristic groups was tested by Wilcoxon ranked sum test 
or Kruskal-Wallis test, when appropriate. Correlation between 
biomarkers was assessed using Spearman correlation analysis. 
Two experienced clinicians (DJS and CB) reviewed patient 
records and scans to assess TTR and OS from surgery.
For the purposes of this study, TTR was defined as the 
time from surgery to relapse or last follow-up, with censor-
ing at LFU, at death from other causes, or at diagnosis of a 
second primary associated with metastases if the patient was 
clinically relapse free from their initial NSCLC. For exam-
ple, if a patient was diagnosed with colorectal cancer, with 
 intra-abdominal nodal and liver metastases, this was inter-
preted for the purposes of this study as representing metastatic 
colorectal cancer unless there were compelling clinical, radio-
logical, or histopathologic data to indicate that it did instead 
indicate recurrent lung cancer, and the patient was censored 
for lung cancer recurrence at the time of diagnosis of the 
colorectal cancer. Similarly, while development of more than 
one lung nodule was generally interpreted as recurrence of the 
original lung cancer, development of a solitary lung nodule 
or mass that appeared clinically and radiologically to be more 
likely a new lung cancer primary was coded as a new primary 
rather than a recurrence. For example, a nodule or mass devel-
oping near a resection margin was coded as a recurrence of 
the original lung cancer, whereas development of a single 
spiculated nodule in a different lobe was interpreted as a new 
primary. The investigators were blinded with respect to bio-
logical markers when making these designations.
Patients who died of other apparent causes and who 
had not had clinically suspected or confirmed relapse by the 
time of death were censored for TTR at their last relapse-free 
 follow-up if they had not had sufficient evaluation shortly 
before their death to conclude with reasonable clinical cer-
tainty that they were free of relapse at the time of death. Again, 
this designation was done in a blinded fashion. We recognized 
that in both this designation and in the designation of recur-
rence versus new primary, we would miss some recurrences, 
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but we chose to err on the side of being more certain of recur-
rence versus being more certain about lack of recurrence.
TTR and OS were estimated using the Kaplan-Meier 
method, and the log-rank test was employed to compare TTR 
between mCAIX staining groups. Cox models were used to 
assess factors associated with TTR. Only the significant fac-
tors with p value of less than 0.05 from univariate Cox model 
were included in the multicovariate Cox model, and backward 
selection was used to eliminate the ones that were not signifi-
cant. p value of less than 0.05 was considered as significant. 
The analysis was performed using SAS 9.3 (SAS Institute 
Inc., Cary, NC). Factors associated with TTR in multicovari-
ate analyses were then tested for their association with OS.
RESULTS
The median age of the 230 patients was 68.2 years (range, 
33.5–90.3), the majority were white (214 of 230, 93.0%), 122 
(53.0%) were women and 108 were men (47.0%), 92 (40.0%) 
were current smokers, 103 (44.8%) were former smokers, 35 
(15.2%) were never smokers, and 182 (79.1%) had stage I 
and 48 (20.9%) had stage II NSCLC. Patient characteristics 
are outlined in Supplementary Table 2 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A547), and tumor IHC 
scores are presented in Supplementary Table 3 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A547). Median 
(range) follow-up for TTR was 82 months (1–158) for those 
who were alive and remained relapse free at LFU. Median 
(range) follow-up for OS for those who remained alive at 
LFU was 80 months (1–158). A total of 52 patients had con-
firmed recurrence and 113 patients died. TTR for the popula-
tion is presented in Supplementary Figure 1 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A548), and OS 
is presented in Supplementary Figure 2 (Supplemental Digital 
Content 3, http://links.lww.com/JTO/A549), with the median 
TTR not being reached and with median OS being 79 months. 
The 2- and 5-year probabilities of maintaining freedom from 
recurrence were 80.7% (95% confidence interval [CI], 75.3%, 
86.4%) and 74.6% (95% CI, 68.6%, 81.2%), respectively. 
When TTR was replotted as an exponential decay (log-linear) 
curve and subjected to nonlinear regression analysis as previ-
ously described,6 those on the terminal flat portion of the curve 
(the “cured” fraction) constituted 70% of the overall popula-
tion, and the estimated half-life to relapse for the 30% relaps-
ing was 20 months (Supplementary Figure 3, Supplemental 
Digital Content 4, http://links.lww.com/JTO/A550).
Table 1 presents univariate Cox model analyses for impact 
of patient and tumor variables on TTR. Nodal stage (N1 versus 
N0), higher number of nodes positive, larger tumor diameter, 
and pathologic stage (II versus I) each correlated with short 
TTR. Among the IHC markers, TTR was significantly shorter 
if any mCAIX staining was detected in patients compared 
with patients whose tumors had no detectable mCAIX staining 
(Fig. 1). The 24- and 60-month probabilities of freedom from 
TAbLE 1.  Univariate Cox Model Analysis for Time to Relapse
Covariate Estimate SE Hazard Ratio
Hazard Ratio 95% 
Confidence Interval p
Histology: adenocarcinoma vs. squamous –0.187 0.285 0.830 0.474–1.452 0.513
gender: male vs. female 0.153 0.277 1.165 0.676–2.007 0.582
Age 0.026 0.014 1.027 0.999–1.055 0.062
Race: white vs. others 0.544 0.721 1.723 0.419–7.086 0.451
Smoking: ever vs. never 0.653 0.471 1.922 0.764–4.834 0.165
Smoking: current vs. never 0.637 0.496 1.890 0.716–4.993 0.199
Smoking: former vs. never 0.668 0.490 1.951 0.746–5.098 0.173
Nodes: N1 vs. N0 1.096 0.302 2.991 1.655–5.406 0.0003
No. of nodes positive 0.383 0.106 1.467 1.191–1.808 0.0003
Tumor diameter (cm) 0.123 0.058 1.131 1.009–1.267 0.035
Pathologic stage: II vs. I 0.945 0.302 2.573 1.425–4.647 0.002
CAIX, membranea 0.002 0.001 1.002 0.999–1.004 0.244
CAIX, cytoplasma 0.002 0.002 1.002 0.999–1.005 0.249
COX2, cytoplasma 0.001 0.001 1.001 0.998–1.004 0.502
CTR1, cytoplasma 0.001 0.002 1.001 0.998–1.005 0.436
CTR1, nucleara 0.000 0.002 1.000 0.997–1.004 0.873
DNMT1, cytoplasma –0.002 0.002 0.998 0.993–1.002 0.256
DNMT1, nucleara 0.004 0.004 1.004 0.996–1.012 0.352
DcR2, cytoplasma 0.004 0.002 1.004 0.999–1.008 0.134
ERCC1, cytoplasma –0.002 0.002 0.998 0.993–1.002 0.343
ERCC1, nucleara –0.001 0.002 0.999 0.995–1.002 0.558
HIF-1α, cytoplasma 0.001 0.002 1.001 0.998–1.004 0.544
HIF-1α, nucleara 0.007 0.006 1.007 0.995–1.019 0.245
(Continued)
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Rb, cytoplasma –0.003 0.002 0.997 0.993–1.002 0.224
Rb, nucleara 0.001 0.002 1.001 0.997–1.004 0.738
SHARP2, cytoplasma –0.003 0.003 0.997 0.992–1.002 0.219
SHARP2, nucleara 0.002 0.002 1.002 0.999–1.005 0.262
Survivin, cytoplasma 0.002 0.002 1.002 0.998–1.005 0.426
Survivin, nucleara 0.002 0.001 1.002 0.999–1.005 0.24
TgF-β, membranea –0.004 0.003 0.996 0.991–1.002 0.16
TgF-β, cytoplasma –0.004 0.002 0.996 0.991–1.000 0.065
VEgF, cytoplasma –0.002 0.002 0.998 0.994–1.003 0.434
VEgF, nucleara 0.005 0.008 1.005 0.989–1.021 0.556
p14ARF, cytoplasma –0.003 0.004 0.997 0.990–1.004 0.431
p14ARF, nucleara 0.005 0.006 1.005 0.994–1.016 0.385
p16INK4, cytoplasma –0.002 0.001 0.998 0.996–1.001 0.268
p16INK4, nucleara –0.001 0.001 0.999 0.997–1.002 0.513
Phospho-Rb, cytoplasma 0.000 0.004 1.000 0.991–1.008 0.923
Phospho-Rb, nucleara 0.001 0.002 1.001 0.996–1.005 0.751
p21WAF1/CIP1, nucleara 0.003 0.002 1.003 0.999–1.008 0.109
p53, nucleara –0.001 0.001 0.999 0.997–1.002 0.491
Ki67, nucleara 0.002 0.002 1.002 0.998–1.005 0.377
CAIX, membrane, >0 vs. 0 0.776 0.323 2.172 1.154–4.090 0.016
CAIX, cytoplasm, >0 vs. 0 0.520 0.521 1.681 0.605–4.672 0.319
COX2, cytoplasm, >0 vs. 0 0.192 0.474 1.212 0.478–3.072 0.685
CTR1, nuclear, >0 vs. 0 0.091 0.313 1.095 0.593–2.022 0.772
DNMT1, cytoplasm, >0 vs. 0 –0.200 0.310 0.818 0.446–1.503 0.518
DNMT1, nuclear, >0 vs. 0 0.480 0.311 1.617 0.880–2.972 0.122
DcR2, cytoplasm, >0 vs. 0 0.393 0.598 1.482 0.459–4.788 0.511
ERCC1, cytoplasm, >0 vs. 0 –0.274 0.291 0.760 0.430–1.345 0.346
ERCC1, nuclear, >0 vs. 0 –0.367 0.289 0.693 0.393–1.221 0.204
HIF-1α, cytoplasm, >0 vs. 0 –0.160 0.521 0.852 0.307–2.366 0.759
HIF-1α, nuclear, >0 vs. 0 0.036 0.341 1.037 0.532–2.021 0.916
Rb, cytoplasm, >0 vs. 0 0.468 1.011 1.597 0.220–11.58 0.643
Rb, nuclear, >0 vs. 0 0.343 0.368 1.409 0.686–2.896 0.351
SHARP2, cytoplasm, >0 vs. 0 0.216 0.723 1.241 0.301–5.123 0.766
SHARP2, nuclear, >0 vs. 0 –0.190 0.524 0.827 0.296–2.311 0.717
Survivin, nuclear, >0 vs. 0 –0.194 0.722 0.824 0.200–3.391 0.789
TgF-β, membrane, >0 vs. 0 0.198 0.285 1.219 0.697–2.130 0.488
TgF-β, cytoplasm, >0 vs. 0 –0.038 0.316 0.963 0.519–1.788 0.905
VEgF, nuclear, >0 vs. 0 0.138 0.357 1.148 0.571–2.309 0.699
p14ARF, cytoplasm, >0 vs. 0 –0.157 0.308 0.854 0.468–1.561 0.609
p14ARF, nuclear, >0 vs. 0 –0.133 0.595 0.875 0.273–2.811 0.823
p16INK4, cytoplasm, >0 vs. 0 –0.342 0.286 0.711 0.405–1.246 0.233
p16INK4, nuclear, >0 vs. 0 –0.335 0.287 0.715 0.408–1.254 0.242
Phospho-Rb, cytoplasm, >0 vs. 0 0.295 0.318 1.343 0.720–2.505 0.354
Phospho-Rb, nuclear, >0 vs. 0 0.002 0.338 1.002 0.517–1.941 0.996
p21WAF1/CIP1, nuclear, >0 vs. 0 –0.103 0.474 0.902 0.356–2.286 0.829
p53, nuclear, >0 vs. 0 –0.076 0.281 0.927 0.535–1.607 0.787
Ki67, nuclear, >0 vs. 0 –0.085 0.522 0.919 0.331–2.555 0.871
aAs a continuous variable.
CAIX, carbonic anhydrase IX; COX2, cyclooxygenase-2; CTR1, copper transporter-1; DNMT1, DNA methyltransferase 1; DcR2, decoy receptor-2; ERCC1, excision repair cross-
complementing rodent repair deficiency, complementation group 1; HIF-1α, hypoxia-inducible factor-1α; Rb, retinoblastoma; SHARP2, enhancer-of-split-and-hairy-related protein; 
TgF-β, transforming growth factor-β; VEgF, vascular endothelial growth factor.
TAbLE 1.  Continued
Covariate Estimate SE Hazard Ratio
Hazard Ratio 95% 
Confidence Interval p
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recurrence were 75.1% (95% CI, 67.3%, 83.7%) and 66.0% 
(95% CI, 57.3%, 76.0%), respectively, for patients with any 
mCAIX staining; and 87.5% (95% CI, 80.2%, 95.5%) and 
84.4% (95% CI, 76.4%, 93.4%), respectively, for patients with 
negative mCAIX staining (p = 0.014, log-rank test).
In multicovariate Cox model analysis, nodal stage (N1 
versus N0) (hazard ratio [HR] = 2.561; 95% CI, 1.409–4.766; 
p = 0.002) and presence versus absence of mCAIX stain-
ing (HR = 2.083; 95% CI, 1.104–3.929; p = 0.023) emerged 
as independent prognostic variables for TTR (Table 2). If 
tumor diameter was forced into the model (HR = 1.068; 
95% CI, 0.928–1.231; p = 0.36), mCAIX remained impor-
tant (HR = 1.923; 95% CI, 0.999–3.705; p = 0.05). Figure 2A 
presents TTR curves for patients with versus without detect-
able mCAIX staining and patients with versus without node 
involvement. The 60-month probability of freedom from 
recurrence for mCAIX negative/N0 patients, mCAIX posi-
tive/N0 patients, mCAIX negative/N1 patients, and mCAIX 
positive/N1 patients was 0.866 (95% CI, 0.783, 0.957), 0.713 
(95% CI, 0.621–0.818), 0.70 (95% CI, 0.467, 1.0), and 0.399 
(95% CI, 0.213, 0.748), respectively.
Five N0 patients (3-stage IA patients with tumors mea-
suring 1.6–2.2 cm and 2-stage IB patients, both with tumors 
measuring 4.5 cm) were judged clinically and radiologically 
to have developed second primary cancers rather than recur-
rences. Of these, two patients were negative for mCAIX on 
IHC and three patients were positive. If they were excluded 
from the analyses, TTR continued to be significantly asso-
ciated with mCAIX (HR = 1.903; 95% CI, 1.114–3.250; 
p = 0.0185). None of the five patients had their new primaries 
compared with their old ones histopathologically.
We then assessed characteristics that correlated with 
mCAIX IHC scores. Table 3 presents median mCAIX scores 
for different patient groups. mCAIX scores were significantly 
higher in squamous cell carcinomas than in adenocarcino-
mas, and less differentiated tumors than better differenti-
ated tumors, with a trend toward higher scores (p = 0.074) in 
patients with EGFR wild-type tumors compared with those 
with EGFR mutations. There was also a trend toward higher 
mCAIX scores in patients with higher stage tumors (p = 0.063 
for N0 versus N1).
Table 4 presents correlations between mCAIX scores 
and other continuous variables. mCAIX scores correlated 
directly with tumor diameter, cytoplasmic SHARP2 scores, 
number of mitoses, tumor necrosis, scores for cytoplasmic 
SHARP2, and nuclear Ki67, nuclear DNMT1, and nuclear 
p53 scores, and they correlated inversely with percent of tumor 
that had papillary characteristics (among adenocarcinomas) 
and with scores for cytoplasmic HIF-1α, cytoplasmic VEgF, 
cytoplasmic DNMT1, nuclear and cytoplasmic CTR1, cyto-
plasmic ERCC1, nuclear and cytoplasmic p16, and nuclear 
p14. mCAIX scores did not correlate with apoptosis or with 
scores for nuclear HIF-1α, nuclear VEgF, SHARP2, or other 
pro-cell-survival or tumor suppressor gene-related factors.
IHC data for mCAIX were evaluable for all three cores 
for 63.2% of patients, for two cores for 23.4% of patients, 
and for only one core for 13.4% of patients. Using data 
from patients in whom at least two cores were evaluable for 
mCAIX, we also assessed impact of heterogeneity of tumor 
mCAIX IHC expression on TTR. Whether just considering 
patients with three evaluable cores (37% mCAIX negative for 
all cores, 45% mCAIX positive for all cores, and 19% hetero-
geneous with 1–2 cores negative, and the remaining positive 
for mCAIX), or also adding in patients with just two evaluable 
cores (38% mCAIX negative in both cores, 45% positive in 
both cores, and 17% positive in one and negative in the other), 
A B
C D FIgURE 1.  Microphotographs illus-trating carbonic anhydrase IX (CAIX) 
immunohistochemistry expression in 
malignant cells of lung cancer tissue 
specimens (×40). A, Combined CAIX 
strong membrane and cytoplasmic 
expressions in a squamous cell car-
cinoma. B, Strong CAIX membrane 
expression in a squamous cell carci-
noma. C, Moderate CAIX cytoplasmic 
expression in an adenocarcinoma. D, 
Lack of CAIX expression in a poorly 
differentiated adenocarcinoma.
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the TTR curve for heterogeneous patients was intermediate 
between the TTR curves for homogeneously negative patients 
and for homogeneously positive patients (p = 0.0471, log-
rank test for trend). If we separately assessed the patients with 
only a single evaluable core, 47% were negative for mCAIX 
and 53% were positive. CIs were wide, but TTR was signifi-
cantly worse for positive patients than for negative patients 
(HR = 6.413; 95% CI, 1.363–30.17; p = 0.0187).
FIgURE 2.  Kaplan-Meier curves for relapse and survival 
by nodal and membrane carbonic anhydrase IX (mCAIX) 
staining status (E/N: no. of events/no. of cases). A, Time to 
relapse: the 60-month probability of freedom from recur-
rence was 0.866 (95% confidence interval [CI], 0.783, 
0.957), 0.713 (95% CI, 0.621–0.818), 0.70 (95% CI, 0.467, 
1.0), and 0.399 (95% CI, 0.213, 0.748) for N0/mCAIX nega-
tive (red), N0/mCAIX positive (blue), N1/mCAIX negative 
(green), and N1/mCAIX positive (black) patients, respectively. 
B, Overall survival: the 60-month probability of being alive 
was 0.745 (95% CI, 0.647, 0.858), 0.639 (95% CI, 0.0.550, 
0.742), 0.727 (95% CI, 0.506, 1.0), and 0.272 (95% CI, 
0.149, 0.497) for N0/mCAIX negative (red), N0/mCAIX 
positive (blue), N1/mCAIX negative (green), and N1/mCAIX 
positive (black) patients, respectively.
TAbLE 2.  Multicovariate Cox Model Analysis for Time to Relapse
Variable Parameter Estimate SE p Hazard Ratio
Hazard 
Ratio 95% Confidence
Interval
Nodes (N1 vs. N0) 0.952 0.311 0.002 2.591 1.409 4.766
Carbonic anhydrase IX membrane, >0 vs. 0 0.734 0.324 0.023 2.083 1.104 3.929
TAbLE 3.  Membrane Carbonic Anhydrase IX in Different 
Patient Groups
Group n
Membrane Carbonic 
Anhydrase IXa  
(Mean ± SD, Median) p
Histopathologic type
  Adenocarcinoma 133 60.4 ± 91.1, 0 <0.0001
  Squamous cell 
carcinoma
77 118.0 ± 104.5, 103
Nodal stage
  N0 169 75.6 ± 97.1, 30 0.063
  N1 41 106.2 ± 108.4, 60
Pathologic stage
  I 164 75.3 ± 96.6, 30 0.077
  II 46 103.9 ± 109.2, 60
Differentiation
  Well 47 63.2 ± 99.4, 0 0.043
  Moderate 87 76.6 ± 96.2, 20
  Poor 75 97.9 ± 103.6, 60
EGFR
  Mutation 12 27.5 ± 56.5, 0 0.074
  Wild type 129 72.3 ± 95.4, 20
KRAS
  Mutation 12 82.1 ± 107.2, 35 0.88
  Wild type 128 66.5 ± 91.7, 18.33
gender
  Female 110 79.6 ± 102.4, 20 0.3879
  Male 100 83.7 ± 97.6, 42.5
Race
  White 194 77.3 ± 96.2, 30 0.090
  Other 16 133.5 ± 130.2, 72.5
Smoking history
  Current 84 81.0 ± 97.4, 37.5 0.605
  Former 94 87.3 ± 104.3, 42.5
  Never 32 66.1 ± 94.4, 15
aMembrane carbonic anhydrase IX range for each category was 0–300.
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In patients with at least two evaluable cores, the pro-
portion of patients with mCAIX heterogeneity was similar for 
patients with adenocarcinomas versus squamous carcinomas 
(17% versus 16%), whereas the proportion of patients with all 
cores being positive was lower in adenocarcinomas compared 
with squamous carcinomas (35% versus 60%, p = 0.0007). 
Similarly, although only 6% of patients with no necrosis noted 
in their samples had heterogeneity between cores compared 
with 17% of patients with at least some degree of tumor necro-
sis, this difference was not significant (p = 0.49), whereas the 
proportion of patients who had all cores positive for mCAIX 
was higher in those with necrosis compared with those with-
out necrosis (48% versus 21%, p = 0.0287).
Although we were primarily interested in TTR, we then 
assessed whether the factors associated with TTR in multi-
covariate Cox models were also associated with OS. When 
nodal stage and mCAIX were taken together as the only fac-
tors considered for a multicovariate OS model, the HR for N1 
versus N0 was 1.918 (95% CI, 1.223, 3.008; p = 0.0133) and 
the HR for mCAIX positive versus negative was 1.762 (95% 
CI, 1.142, 2.720; p = 0.0105). The 60-month probability of 
OS for mCAIX negative/N0 patients, mCAIX positive/N0 
patients, mCAIX negative/N1 patients, and mCAIX positive/
N1 patients was 0.745 (95% CI, 0.647, 0.858), 0.639 (95% CI, 
0.0.550, 0.742), 0.727 (95% CI, 0.506, 1.0), and 0.272 (95% 
CI, 0.149, 0.497), respectively (Fig. 2B).
DISCUSSION
In determining who should be considered for adjuvant ther-
apies, it helps to be able to define those patients who are at highest 
risk of tumor relapse. In this study, we found that for patients with 
resected stage I–II NSCLC, there appeared to be a plateau on the 
TTR curve, with approximately 70% of patients projected to be 
on this cured plateau. TTR differs from “relapse-free survival” 
since our patients were censored if they died of other apparent 
causes, while either relapse or death from any causes is counted 
as a relapse-free survival event. We wished to maximize the prob-
ability of defining factors associated with tumor biology without 
contamination from factors associated with death from comor-
bidities or second primary malignancies. Patients who died of 
uncertain causes without recent reevaluation of relapse status 
were censored at the time of last evaluation for relapse if they 
were relapse free at that time. Our approach (designed to improve 
biological and clinical relevance of our assessments) decreased 
statistical power by decreasing the number of evaluable “events” 
and by decreasing the length of follow-up for censored patients 
and would have missed any relapses occurring after LFU.
In keeping with the well-established impact of stage on 
outcome,3 node involvement emerged as the most important pre-
dictor of relapse. Presence of membrane staining for carbonic 
anhydrase IX (CAIX) was the only other factor that correlated 
with outcome in multicovariate analysis. Although mCAIX cor-
related with both tumor size and with Ki67, mCAIX correlated 
independently with TTR while size and Ki67 did not.
CAIX messenger RNA (mRNA)7,8 and protein (by 
IHC)9–12 are frequently expressed in resected NSCLCs, with 
CAIX expression being particularly common in squamous 
cancers.9,13 It is unknown whether this association of CAIX 
TAbLE 4.  Factors Correlating with Membrane Carbonic 
Anhydrase IX Score
Factora n
Spearman 
Coefficient p
Tumor diameter 204 0.243 0.0005
Adenocarcinoma composition (% of tumor made up by each histopathologic 
subtype)
  % Acinar 133 0.121 0.167
  % Lepidic 133 –0.126 0.148
  % Mucinous 133 0.018 0.836
  % Papillary 133 –0.212 0.014
  % Solid 133 0.094 0.282
  % Micropapillary 133 –0.067 0.44
Hypoxia-associated markers
  nHIF-1α 208 –0.016 0.818
  cHIF-1α 208 –0.153 0.027
  nVEgF 188 0.120 0.100
  cVEgF 188 –0.143 0.051
  nSHARP2 187 –0.044 0.551
  cSHARP2 187 0.255 0.0004
Proliferation-associated markers
  Mitoses 209 0.203 0.003
  nKi67 200 0.212 0.003
  nDNMT1 201 0.192 0.006
  cDNMT1 201 –0.240 0.0006
  nCTR1 198 –0.208 0.003
  cCTR1 198 –0.228 0.001
Cell death- or survival-associated markers
  Necrosis 209 0.260 0.0001
  Apoptosis 195 0.060 0.408
  Cytoplasmic decoy receptor-2 191 0.006 0.929
  nSurvivin 205 0.052 0.463
  cSurvivin 205 –0.074 0.294
  cTgF-β 203 –0.135 0.055
  mTgF-β 203 –0.125 0.077
DNA repair and inflammation markers
  nERCC1 203 –0.049 0.49
  cERCC1 203 –0.151 0.031
  Cytoplasmic cyclooxygenase-2 174 0.061 0.42
Tumor suppressor genes and related molecules
  nP53 209 0.157 0.024
  nP21 196 0.081 0.256
  nRb 204 –0.029 0.677
  cRb 204 –0.125 0.074
  nPhospho-Rb 176 0.136 0.071
  cPhospho-Rb 176 –0.018 0.814
  nP16 202 –0.14 0.043
  cP16 202 –0.14 0.041
  nP14 209 –0.135 0.051
  cP14 209 –0.09 0.191
ac, cytoplasmic; m, membrane; n, nuclear.
HIF-1α, hypoxia-inducible factor-1α; VEgF, vascular endothelial growth factor; 
SHARP2, enhancer-of-split-and-hairy-related protein; DNMT1, DNA methyltransferase 1; 
CTR1, copper transporter-1; TgF-β, transforming growth factor-β; ERCC1, excision repair 
cross-complementing rodent repair deficiency, complementation group 1; Rb, retinoblastoma.
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with squamous lung cancers is related to the frequent loss of 
the von Hippel-Lindau (VHL) tumor suppressor gene that is 
seen in NSCLC.14 VHL loss of heterozygosity15 and meth-
ylation/downregulation16 are common in NSCLC and occur 
in squamous cell carcinomas much more frequently than in 
adenocarcinomas. In other tumor types, mCAIX expression 
was noted in pheochromocytomas only if they were associated 
with VHL germline mutations,17 whereas in renal cell carcino-
mas, CAIX expression was perinecrotic in tumors with intact 
VHL systems but was diffuse in VHL-defective tumors.18
Tumor subtype may also be important. We found par-
ticularly low expression in lung adenocarcinomas with a high 
papillary component. Of interest, CAIX expression is also 
lower in papillary renal cell carcinomas than that in clear cell 
kidney carcinomas,19,20 and CAIX expression also varies with 
subtype in ovarian21 and breast22–25 cancers.
CAIX catalyzes the reversible hydration of carbon diox-
ide to carbonic acid and is up-regulated in cancers to help 
maintain physiologic intracellular pH despite high glycoly-
sis rates.26 While maintaining a physiologic intracellular pH, 
it acidifies the extracellular space.26 CAIX may promote a 
metastatic or invasive phenotype by reducing cell adhesion,27 
increasing cell invasiveness28 and mobility and migration,27 
inducing angiogenesis,27 and activating proteases.27
CAIX expression in normal tissues is generally substan-
tially less than that in tumors.7,8,12,13 Hypoxia leads to increased 
CAIX gene expression,29 transcription,30 and protein expres-
sion31,32 in several types of tumor cell lines, and both low glu-
cose and low bicarbonate increase CAIX transcription and 
protein expression in hypoxic cells.30
In resected NSCLC, tumor oxygenation correlated 
negatively with CAIX IHC staining,33 although there has not 
been consistent correlation between tumor hypoxia and CAIX 
expression in vivo,32 and for at least some tumor types, there 
may be both hypoxia-driven and hypoxia-independent CAIX 
signaling pathways.34,35
In keeping with our findings, most (but not all)36 other 
NSCLC studies assessing CAIX IHC11,13,37–39 or mRNA7,33,40 
tumor expression or plasma levels37 have also reported an 
association of high expression with worse overall11,13,33,37,38,40 
or disease-free7,13,33,39 survival, with the greatest negative 
impact on survival being noted in later stage NSCLCs and 
in squamous cell carcinomas.33 Although we found the stron-
gest correlation between mCAIX staining and TTR, others 
had previously noted perinuclear CAIX staining to be par-
ticularly important.11,38
High tumor cell CAIX expression has also been associ-
ated with worse prognosis in sarcomas,41,42 gliomas,28,43 neuro-
blastomas,44 papillary renal cell carcinomas,45 and carcinomas 
of the breast,23,24,46,47 head and neck,48 nasopharynx,49 ovary,21 
cervix,50 and rectum,51 but CAIX expression did not correlate 
with outcome in meningiomas52 or in carcinomas of the pan-
creas53 or prostate54 and was paradoxically associated with 
improved outcome in renal clear cell carcinomas.19,55,56 High 
CAIX levels in tumor stromal cells may also be associated 
with poor outcome.57,58
In our study, mCAIX expression correlated with tumor 
size, with markers of proliferation (including Ki67 and number 
of mitoses), with poor differentiation, and with necrosis (but 
not apoptosis), and we noted a trend (p = 0.063) toward higher 
mCAIX expression in N1 versus N0 tumors. Other studies 
that included a variety of tumor types also noted a correlation 
of CAIX expression with tumor size,47,50 mitoses,44 Ki67,10,43,47 
lack of differentiation,13,23,25,43,46,47,58 necrotic11,23,31,39,59 or 
perinecrotic areas,18,31,43,59,60 and higher stage,13,31,44 although 
some of these factors failed to correlate with CAIX expres-
sion in still other studies.9,20,21,46,50,55,61,62
CAIX and VEGF are both target genes of the transcrip-
tion factor HIF-1α63,64 that is generally induced by hypoxia but 
that may also be induced by Src.64 Although mCAIX expres-
sion in our patients did correlate with cytoplasmic expression of 
the hypoxia-inducible factor SHARP2, it did not correlate with 
HIF-1α or VEgF nuclear expression but paradoxically corre-
lated inversely with HIF-1α and VEgF cytoplasmic expression. 
Results have been variable in other studies. In various tumor 
types, CAIX expression has correlated with HIF-1α expression 
in some studies39,43,47,49,52,65 but not in others.61,65,66 HIF-1α may 
also lose its transcriptional ability (e.g., through repression by 
p53) such that CAIX induction does not happen despite high 
HIF-1α expression.67 Furthermore, CAIX expression may cor-
relate with HIF-1α expression in tumors in which the HIF-1α 
expression is perinecrotic but not in tumors in which HIF-1α 
expression is diffuse throughout the tumor.60 Also, CAIX has 
a much longer half-life in tissues (approximately 38 hr)30 than 
does HIF-1α, and HIF-1α expression will rapidly decrease in 
tumor areas that have low nutrient levels, whereas CAIX will 
persist due to its longer half-life.68 In addition, in the absence 
of hypoxia and  HIF-1α, CAIX expression may be up-regulated 
by high cell density through the PI3K pathway,69 and increased 
expression of CAIX in the absence of hypoxia may also occur 
with hypomethylation of the CAIX gene promoter.70
Similarly, some previous studies have found positive 
correlations between CAIX and VEgF expression,33,43,52,59 
whereas others have not,34,50,71 and still others have found an 
inverse correlation between CAIX and VEgF expression,56 
similar to what we found. Lack of a consistent correlation 
between CAIX and VEgF may be due in part to the fact that 
upon reoxygenation of tissues, VEgF mRNA declines rap-
idly, whereas CAIX mRNA expression persists for more than 
72 hours.59
In addition to serving as a prognostic marker, CAIX 
could also potentially serve as a therapeutic target or as a 
predictive marker for efficacy of other therapies. Therapies 
targeting CAIX were effective in preclinical models,27 and 
some are in early stages of clinical investigation.72 Moreover, 
high CAIX expression in NSCLC may be associated with 
decreased efficacy of radiotherapy,9 and interference with 
CAIX strongly augments the efficacy of both radiotherapy 
and some chemotherapy agents in preclinical systems.28 
Conversely, activity of targeted agents and cytokines may be 
augmented in renal cell carcinomas with high CAIX expres-
sion,73 and tumor uptake and efficacy of some chemotherapy 
agents that are weak acids could potentially be augmented by 
the acidic milieu promoted by CAIX.74
In summary, high CAIX expression is associated with 
poor prognosis across a wide range of tumor types, and we 
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found that mCAIX expression in particular was associated 
with an increased risk of relapse in our stage I–II NSCLC 
patients. Based on these observations, it would be reasonable 
to assess mCAIX expression further as a prognostic factor in 
NSCLC, and given the range of studies that have found an 
association between CAIX expression and poor outcome in 
NSCLC, it would be reasonable in advanced NSCLC to assess 
efficacy of new investigational agents targeting CAIX.
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